Skip to main content

Table 1 Summary statistics on plasma concentrations of AZD3778 (μmol/L).

From: Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis

Variable n Gmean CV Min Median Max
Day 1, post-dose 34 5.49 38.5 2.45 5.83 10.40
Day 8, pre-dose 24 2.51 98.0 0.29 3.41 6.27
Day 8, post dose 34 7.77 44.4 3.14 7.95 20.10
Day 9, pre-dose 26 2.21 106.4 0.32 2.79 8.13
Day 9, post dose 34 7.55 36.0 3.15 7.51 15.60
Day 10, pre-dose 34 2.53 71.0 0.28 2.95 7.84
Day 10, post dose 34 7.19 36.5 3.29 7.34 13.50
  1. Plasma levels of AZD3778 were stable during the last three days of the treatment series.